Effects of mean platelet volume and platelet counts on peripheral biodegradable stent restenosis

Engin Akgül; Mesut Engin; Ahmet Fatih Özyazıcıoğlu

doi:10.28982/josam.569158

Authors

Engin Akgül https://orcid.org/0000-0001-7361-0430
Mesut Engin https://orcid.org/0000-0003-2418-5823
Ahmet Fatih Özyazıcıoğlu https://orcid.org/0000-0001-8642-5664

DOI:

https://doi.org/10.28982/josam.569158

Keywords:

Biodegradable stent, Peripheral arterial disease, Platelet counts, Mean platelet volume

Abstract

Aim: Thrombocytes play a key role in atherosclerosis and acute vascular events. The purpose of this study is to investigate the association between mean platelet volume (MPV), platelet counts as well as other hematological parameters and biodegradable stent re-stenosis.

Methods: 53 patients who underwent percutaneous biodegradable peripheral stent placement procedure were included in this retrospective cohort study. Blood samples were collected a day before the operation. Patients were followed for a mean of 6 months and Doppler ultrasonography (DUSG) was performed for control examination. According to the DUSG results, patients were divided into two groups: Group 1 included patients with ≥50% in-stent re-stenosis and Group 2, with <50% in-stent re-stenosis.

Results: The mean age of the patients was 58.1 (6.7) years. 6 (11.3%) patients were female and 47 (88.7%) patients were male. Eight (15%) had iliac artery and 45 (84.9%) had superficial femoral artery stenosis. Doppler US reports showed that 11 (20.8%) patients had ≥50% in-stent re-stenosis (Group 1). Re-stenosis rates were higher at younger ages (P=0.020). There was no statistically difference between the groups in terms of gender (P=0.636), MPV (P=0.210), PLT counts (P=0.129) or any other hematologic parameters.

Conclusion: Several studies have shown that some blood parameters, especially MPV, are effective on coronary and peripheral stent stenosis. In our study, we found that none of the hematologic or common blood parameters can predict biodegradable stents re-stenosis.

Downloads

Download data is not yet available.

References

Karabay Ö, Karaçelik M, Yılık L, Tekin L, İriz A, Kumdereli S, et al Ischemic peripheral arterial disease: A screening survey. Turk Gogus Kalp Dama. 2012;20(3):450-7. DOI: 10.5606/tgkdc.dergisi.2012.089

David B, Edward W, Chrisopher T, A New Wave in Treatment of Vascular Occlusive Desease: Biodegradable Stents- Clinical experience and Scientific Principles. JVIR. 2009; 20(3):315-24. DOI: 10.1016/j.jvir.2008.11.007

Eren R, Doğu MH, Koç A, Altındal Ş, Yokuş O, Suyanı E. The association of mean platelet volume and platecrit and bone marrow fibrosis in patients with essential thrombocythemia: A cohort study. J Surg Med. 2019;3(2):176-9. DOI: 10.28982/josam.525751

Bıyık İ, Aslan MM, Keskin F. Association between platelet indices and missed abortion. J Surg Med. 2019;3(8):549-52 DOI: 10.28982/josam.530098

Werner M, Schmidt A, Scheinert S, Banning-Eichenseer U, Ulrich M, Bausback Y, et al. Evaluation of the Biodegradable Igaki-Tamai Scaffold After Drug-Eluting Balloon Treatment of De Novo Superficial Femoral Artery Lesions: The GAIA-DEB Study. J Endovasc Ther. 2016;23(1):92-7. DOI: 10.1177/1526602815620618

Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123(7):779-97. DOI: 10.1161/CIRCULATIONAHA.110.971606

Nishio S, Kosuga K, Igaki K, Okada M, Kyo E, Tsuji T, et al. Long-Term (>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation. 2012;15:125(19):2343-53. DOI: 10.1161/CIRCULATIONAHA.110.000901

Werner M, Micari A, Cioppa A, Vadalà G, Schmidt A, Sievert H, et al Evaluation of the biodegradable peripheral Igaki-Tamai stent in the treatment of de novo lesions in the superficial femoral artery: the GAIA study JACC. Cardiovasc Interv. 2014;7(3):305-12. DOI: 10.1016/j.jcin.2013.09.009

Sansanayudh N, Muntham D, Yamwong S, Sritara P, Akrawichien T, Thakkinstian A. The Association between mean platelet volume and cardiovascular risk factors. Eur J Intern Med. 2016;30(5):37-42. DOI: 10.1016/j.ejim.2015.11.028

Yang A, Pizzulli L, Lüderitz B. Mean platelet volume as marker of restenosis after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thromb Res. 2006;117(4):371-7. DOI: 10.1016/j.thromres.2005.04.004

Berger JS, Eraso LH, Xie D, Sha D, Mohler ER. Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999-2004. Athersclerosis. 2010;213(2):586-91. DOI: 10.1016/j.atherosclerosis.2010.09.010

Li S, Wang C, Zhong XW, Li HQ, FUXQ, Ran XW. Variance of mean platelet volume in subjects with normal glucose tolerance, impaired glucose regulation and type 2 diabetic mellitus and its relationship with diabetic peripheral artery disease. Zhonghua Yi Xue Za Zhi. 2012;92(2):232-5. PMID:22490792

Karauzum K, Bildirici U, Dervis E, Karauzum I, Baydemir C. Preprocedural Mean Platelet Volume Level Is a Predictor of In-Stent re-stenosis of the superficial femoral Artery Stents in Follow-Up. Cardiol Res Pract. 2018:4572629. DOI: 10.1155/2018/4572629

Dai Z, Gao J, Li S, Li R, Chen Z Mean Platelet Volume as a Predictor for Restenosis After Carotid Angioplasty and Stenting. Stroke. 2018;49(4):872-6. DOI: 10.1161/STROKEAHA.117.019748

Chan YC, Cheng SW, Cheung GC Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease. J Vasc Surg. 2015;62(5):1201-9. DOI: 10.1016/j.jvs.2015.05.030

Miller AJ, Takahashi EA, Harmsen WS, Mara KC, Misra S Treatment of Superficial Femoral Artery Restenosis. J Vasc Interv Radiol. 2017;28(12):1681-6. DOI: 10.1016/j.jvir.2017.07.032